CRNX
Price
$29.40
Change
+$0.31 (+1.07%)
Updated
Aug 21 closing price
Capitalization
2.77B
76 days until earnings call
IDYA
Price
$24.63
Change
+$0.31 (+1.27%)
Updated
Aug 21 closing price
Capitalization
2.16B
81 days until earnings call
Interact to see
Advertisement

CRNX vs IDYA

Header iconCRNX vs IDYA Comparison
Open Charts CRNX vs IDYABanner chart's image
Crinetics Pharmaceuticals
Price$29.40
Change+$0.31 (+1.07%)
Volume$1.56M
Capitalization2.77B
IDEAYA Biosciences
Price$24.63
Change+$0.31 (+1.27%)
Volume$766.28K
Capitalization2.16B
CRNX vs IDYA Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. IDYA commentary
Aug 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and IDYA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 22, 2025
Stock price -- (CRNX: $29.40 vs. IDYA: $24.63)
Brand notoriety: CRNX and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 190% vs. IDYA: 75%
Market capitalization -- CRNX: $2.77B vs. IDYA: $2.16B
CRNX [@Biotechnology] is valued at $2.77B. IDYA’s [@Biotechnology] market capitalization is $2.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 5 bearish.
  • IDYA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both CRNX and IDYA are a bad buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а -0.98% price change this week, while IDYA (@Biotechnology) price change was +1.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.66%. For the same industry, the average monthly price growth was +23.52%, and the average quarterly price growth was +24.22%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

IDYA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+1.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.77B) has a higher market cap than IDYA($2.16B). IDYA YTD gains are higher at: -4.163 vs. CRNX (-42.500). IDYA has higher annual earnings (EBITDA): -380.2M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. IDYA (670M). IDYA has less debt than CRNX: IDYA (26.6M) vs CRNX (49.9M). IDYA has higher revenues than CRNX: IDYA (7M) vs CRNX (1.39M).
CRNXIDYACRNX / IDYA
Capitalization2.77B2.16B128%
EBITDA-419.62M-380.2M110%
Gain YTD-42.500-4.1631,021%
P/E RatioN/AN/A-
Revenue1.39M7M20%
Total Cash1.2B670M179%
Total Debt49.9M26.6M188%
FUNDAMENTALS RATINGS
CRNX vs IDYA: Fundamental Ratings
CRNX
IDYA
OUTLOOK RATING
1..100
6374
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
6870
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8248
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (62) in the null industry is in the same range as CRNX (86) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (68) in the Pharmaceuticals Major industry is in the same range as IDYA (70) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

CRNX's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Price Growth Rating (48) in the null industry is somewhat better than the same rating for CRNX (82) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew somewhat faster than CRNX’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXIDYA
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
76%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 7 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
72%
Aroon
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APPIX16.28N/A
N/A
Appleseed Institutional
TQCIX19.67N/A
N/A
Touchstone Dividend Equity Institutional
EAASX34.11N/A
N/A
Eaton Vance Atlanta Capital SMID-Cap A
PORIX60.85N/A
N/A
Trillium ESG Global Equity Institutional
FSBKX21.62-0.06
-0.28%
Federated Hermes Global Allocation R

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+1.07%
XNCR - CRNX
62%
Loosely correlated
-0.93%
RVMD - CRNX
57%
Loosely correlated
+0.88%
IDYA - CRNX
57%
Loosely correlated
+1.27%
NRIX - CRNX
56%
Loosely correlated
+1.26%
SYRE - CRNX
56%
Loosely correlated
+2.63%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with SYRE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+1.27%
SYRE - IDYA
61%
Loosely correlated
+2.63%
IMNM - IDYA
61%
Loosely correlated
+3.97%
NRIX - IDYA
61%
Loosely correlated
+1.26%
CGON - IDYA
61%
Loosely correlated
+1.76%
XENE - IDYA
58%
Loosely correlated
+1.43%
More